doc.guandang.net
Oncotarget, November, Vol.2, No 11
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells
Genevieve L. Weber1, Marie-Odile Parat2, Zev A. Binder1, Gary L. Gallia1, Gregory J. Riggins1
1 2
Ludwig Collaborative Laboratory, Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD
School of Pharmacy, University of Queensland, Australia
Correspondence to: Gregory J. Riggins, email: griggin1@jhmi.eduKeywords: glioblastoma, PIK3CA, PIK3R1, invasion, PI3K, pathway analysis
Received: October 27, 2011, Accepted: October 28, 2011, Published: November 5, 2011
Copyright: © Weber et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
AbstrAct:
Glioblastoma multiforme (GBM) is a highly invasive and deadly brain tumor. Tumor cell invasion makes complete surgical resection impossible and reduces the efficacy of other therapies. Genome-wide analyses of mutations, copy-number changes, and expression patterns have provided new insights into genetic abnormalities common in GBM. We analyzed published data and identified the invasion and motility pathways most frequently altered in GBM. These were most notably the focal adhesion and integrin signaling, and extracellular matrix interactions pathways. We mapped alterations in each of these pathways and found that they included the catalytic PIK3CA and regulatory PIK3R1 subunit genes of the class IA PI3K. Knockdown of either of these genes separately in GBM cell lines by lentiviral-mediated shRNA expression resulted in decreased proliferation, migration, and invasion in all lines tested. FAK activity was reduced by knockdown of either PIK3CA or PIK3R1, and MMP2 levels were reduced by knockdown of PIK3R1. We conclude that PIK3R1, like PIK3CA, is a potential therapeutic target in GBM and that it also influences tumor cell growth and motility.
INtrODUctION
Glioblastoma multiforme is the most common primary brain malignancy, with a current median survival of approximately 15 months in patients with newly diagnosed disease following treatment with surgery, chemotherapy and radiotherapy [1]. The invasive nature of GBM has been frequently implicated as a key feature of GBM’s resistance to therapy [2-5]. Targeting pathways involved in the invasive phenotype of the tumor could be an important component of successful treatment in combination with strategies that more directly target the cancer cells.
The sequencing of 20,661 gene coding regions in multiple glioblastoma tumors was a significant milestone in understanding the genetic basis of GBM [6]. In this analysis, Parsons, et al utilized automated sequencing approaches and Illumina SNP arrays to identify mutations and copy number changes, respectively, in genes in 22 glioblastomas [6]. Genes found to harbor alterations in
at least 2/22 tumors, and which had mutation frequencies of >10 mutations per Mb of DNA sequenced, were subsequently re-sequenced in an additional 83 tumors as validation. This sequencing of 22 GBM exomes, along with detection of genomic amplifications and homozygous deletions, likely identifies the majority of the mutated genes driving tumor formation and progression in glioblastoma.
One challenge has been to identify the genetic alterations that occur during tumor development that are functionally involved in driving tumor formation and progression. Carter et al developed the Cancer-specific High-throughput Annotation of Somatic Mutations (CHASM) program to systematically identify mutations in tumors that are likely to drive the cancer phenotype [7]. The CHASM program utilizes 49 predictive features to estimate the likelihood that a specific mutation in question is a driver, rather than a passenger mutation [7]. This group applied CHASM to a list of 607 missense mutations found by Parsons et al in GBM [6, 7]. The
on migration and invasion in ovarian cancer cell lines ES-2 and SKOV-3, and investigated the links between sex steroids and the PI3K/AKT pathway. ...
Tumour invasion; Signalling pathway; Rho GTPases ... PI3K–Akt, TGF –Smads, ILK–Akt, and Wnt–...neighbouring cells; (ii) migration in the ...
cells migration and invasion in concert with activating the PI3K/AKT signaling pathway; (iii) Elevated level of PRL-1 is associated with intravascular ...
cell junctions allowing migration and invasion EGFR...PI3K Akt mTOR Ras PI3K MAPK Akt mTOR Cox2 ...pathway promotes tumor expansion and invasion ...
no cell junctions allowing migration and invasion ...TGFbR Ras PI3K MAPK FGFR PDGFR Akt mTOR Cox2 ...pathway promotes tumor expansion and invasion ...
tumor progression, invasion, and therapeutic ...one of which is Wnt/b-catenin signaling pathway...cell proliferation, survival, and migration, ...
tumor progression, invasion, and therapeutic ...one of which is Wnt/b-catenin signaling pathway...cell proliferation, survival, and migration, ...
热门文档